Results 21 to 30 of about 20,621 (305)
Pharmacogenetic Study of Deferasirox, an Iron Chelating Agent [PDF]
PLoS ONE, 2013 Abstract Abstract 2060 Transfusion associated iron overload induce systemic toxicity. Deferoxamine had been used to reduce iron induced toxicities by chelating iron but it is a short acting drug and needs parenteral administration.
Ji Won Lee +12 more
openalex +6 more sources
A Speciation Study on the Perturbing Effects of Iron Chelators on the Homeostasis of Essential Metal Ions. [PDF]
PLoS ONE, 2015 A number of reports have appeared in literature calling attention to the depletion of essential metal ions during chelation therapy on β-thalassaemia patients.
Guido Crisponi +6 more
doaj +1 more source
Iron Chelating Agents: Promising Supportive Therapies in Severe Cases of COVID-19? [PDF]
Trends in Pharmaceutical Sciences, 2020 Dear Editor, On December 2019, new cases of COVID-19 pneumonia were reported from Wuhan city of China that were consequences of 2019-nCoV or SARS-CoV-2 infection (1).
Parisa Ghasemiyeh +1 more
doaj +1 more source
Iron-chelating agents for treating malaria
Cochrane Database of Systematic Reviews, 2003 Researchers are exploring the effects of adding treatments to the main antimalarial regimens in an attempt to reduce mortality from Plasmodium falciparum. Iron chelation is one potential chemotherapeutic adjuvant treatment. Before advocating adjunctive therapy, the effects of iron chelators in improving patient outcomes need to be examined.To assess ...
Smith, H. J., Meremikwu, M.
openaire +5 more sources
Impact of Sappan Wood Extract as Iron Chelator Adjuvant on Iron Concentration and Macrophage Polarization in Rat Spleen [PDF]
Iranian Journal of Medical SciencesBackground: Iron accumulation in the spleen of thalassemia patients disrupts macrophage polarization, impairs immune function, and increases mortality.
Mohammad Ghozali +6 more
doaj +1 more source
Detection of endocrine disorders in young children with multi-transfused thalassemia major
Italian Journal of Pediatrics, 2021 Background Beta thalassemia major (TM) is the most common inherited genetic disorder worldwide. Patients are at risk of iron overload, which leads to various forms of tissue damage, including endocrinopathies.
Ramadan A. Mahmoud +2 more
doaj +1 more source
Revista Brasileira de Hematologia e Hemoterapia, 2013 In the absence of an iron chelating agent, patients with beta-thalassemia on regular transfusions present complications of transfusion-related iron overload.
Monica Pinheiro de Almeida Verissimo +10 more
doaj +1 more source
Molecular Neurodegeneration, 2017 The homeostasis of iron is vital to human health, and iron dyshomeostasis can lead to various disorders. Iron homeostasis is maintained by iron regulatory proteins (IRP1 and IRP2) and the iron-responsive element (IRE) signaling pathway.
Zhi Dong Zhou, Eng-King Tan
doaj +1 more source
Applied Sciences, 2021 In this paper, chelating agents were introduced as standalone fluids for enhancing the oil recovery from carbonate and sandstone reservoirs. Chelating agents such as glutamic acid di-acetic acid (GLDA), ethylene-diamine-tetra acetic acid (EDTA), and ...
Amjed Hassan +2 more
doaj +1 more source
Iron Chelators as Potential Therapeutic Agents for Parkinsons Disease [PDF]
Current Bioactive Compounds, 2008 Parkinson's disease (PD) is a neurological disorder characterized by the progressive impairment of motor skills in patients. Growing evidence suggests that abnormal redox-active metal accumulation, caused by dysregulation, plays a central role in the neuropathology of PD. Redox-active metals (e.g.
Carlos A, Perez, Yong, Tong, Maolin, Guo
openaire +2 more sources